Organon & Co
USUSDOrganon & Co (US:OGN) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- organon.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- Oss, United States
- PDG
- Joseph T. Morrissey
- Employés
- 10 000
- Fondée
- 1923
- Actions en circulation
- Flottant
- 242.99 M
- Capitalisation boursière
- 3.6 Md USD
- Initiés
- 0.46%
- Investisseurs institutionnels
- 84.8%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- ISIN
- US68622V1061
- LEI
- 549300AMCKY57OK2CO56
- Taux de distribution
- 8.6%
- FCF
- 567 M USD3%
- Dette
- 8.55 Md USD13 ans de FCF
- Ancienneté du dividende
- 5 ans
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Dividendes
Organon & Co (OGN) verse des dividendes trimestriels. Au cours des 12 derniers mois, 0.08 USD par action ont été versés (versements : 4). Cela représente environ 0.58% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 13.11.2026. Historique des dividendes ininterrompu : 5 ans.
| Date ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 0.0200 USD | 0.1/0.6 % | trimestriel | US:OGN |
| 2026-05-11 | 2026-06-11 | 0.0200 USD | 0.1/0.6 % | trimestriel | US:OGN |
| 2026-02-23 | 2026-03-12 | 0.0200 USD | 0.1/0.6 % | trimestriel | US:OGN |
| 2025-11-20 | 2025-12-11 | 0.0200 USD | 0.1/2.5 % | trimestriel | US:OGN |
| 2025-08-15 | 2025-09-11 | 0.0200 USD | 0.1/4.4 % | trimestriel | US:OGN |
| 2025-05-12 | 2025-06-12 | 0.0200 USD | 0.1/4.2 % | trimestriel | US:OGN |
| 2025-02-24 | 2025-03-13 | 0.2800 USD | 2.0/≈8.1 % | trimestriel | US:OGN |
| 2024-11-12 | 2024-12-12 | 0.2800 USD | 2.0/≈8.1 % | trimestriel | US:OGN |
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 12.21% | 32.06 M | 2026-06-30 |
| Pentwater Capital Manage… | 6.89% | 18.1 M | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 16 M | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.76% | 15.13 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.54% | 11.91 M | 2026-06-30 |
| State Street Corporation | 3.68% | 9.66 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.33 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 6.02 M | 2026-06-30 |
| Goldman Sachs Group Inc | 1.98% | 5.2 M | 2026-06-30 |
| UBS Group AG | 1.85% | 4.86 M | 2026-06-30 |
| Geode Capital Management… | 1.83% | 4.82 M | 2026-06-30 |
| Alliancebernstein L.P. | 1.81% | 4.75 M | 2026-06-30 |
| Man Group PLC | 1.59% | 4.18 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.45% | 3.82 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 3.01 M | 2026-06-30 |
| NexPoint Funds I-NexPoin… | 1.03% | 2.71 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 0.94% | 2.47 M | 2026-08-31 |
| iShares Trust-iShares S&… | 0.89% | 2.35 M | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.54% | 1.41 M | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 1.3 M | 2026-07-31 |
| ALI KEVIN (Chief Executi… | ≈0.11% | 282 731 | 2025-05-05 |
| WALSH MATTHEW M (Chief F… | ≈0.08% | 212 746 | 2026-03-31 |
| MORRISSEY JOSEPH T JR (C… | ≈0.05% | 123 123 | 2026-03-31 |
| STAHLER RACHEL A (Chief… | ≈0.04% | 116 105 | 2026-03-31 |
| FALCIONE AARON (Officer) | ≈0.04% | 101 431 | 2026-03-31 |
| WEAVER KIRKE (General Co… | ≈0.04% | 92 639 | 2026-03-31 |
| NISITA VITTORIO (Officer… | ≈0.03% | 70 619 | 2026-03-31 |
| KARP DANIEL (Officer) | ≈0.03% | 69 547 | 2026-03-31 |
| HOLZBAUR LYNETTE (Office… | ≈0.02% | 52 850 | 2026-05-06 |
| COX CARRIE SMITH (Office… | — | — | 2025-11-12 |
